LATEST NEWS

IPPG Building

BIOMILLENIA moves to new offices

Paris, France, February 23rd, 2016 BIOMILLENIA will move its laboratories and office to the newly built business incubator at the Pierre-Gilles de Gennes Institute in Paris, France. Since starting operations in 2015, BIOMILLENIA entered into several agreements with leading companies in the US and Europe for developing improved versions of enzymes and production strains. The relocation of BIOMILLENIA to the IPGG …

main background

BIOMILLENIA partners with SOUFFLET on BIOprospect co-development of cellulolytic and proteolytic enzymes

Paris, France, December 1st, 2015—BIOMILLENIA SAS announces to partner with SOUFFLET BIOTECHNOLOGIES, a division of the french leading agricultural company SOUFFLET on co-developing novel enzymes within a BIOprospect project framework. BIOMILLENIA’s BIOprospect offering creates novel industry solutions for the manufacturing of biology-based products by exploring new enzymes and microbes from natural samples at unprecedented throughput. Ultrasensitive detection of enzyme activities …

main background

BIOMILLENIA launches the BIOMILLENIA DIMENSION 300X products for more efficient development of bio-based chemicals and natural products

Paris, France, September 24, 2015—BIOMILLENIA SAS today launched the new BIOMILLENIA DIMENSION 300X products for the development of bio-based chemicals and natural products. The product BIOprospect creates novel industry solutions for the manufacturing of bio-based chemicals by exploring new enzymes and microbes from natural samples at unprecedented throughput. Ultrasensitive detection of enzyme activities even allows the analysis of microbes that …

IPPG Building

Screen 30 million enzyme or strain variants in only a single day

Paris, France, September 10, 2015—BIOMILLENIA installed the second DIMENSION 300X platform, effectively doubling the company’s screening output to approximately 30.000.000 enzyme variants or microbial strains in a single day! Imagine what projects can be accomplished with such ultrahigh-throughput screening and assay capabilities. Let us know your ideas at info[at]biomillenia.com!